论文部分内容阅读
目的：为了探索不同剂量的NVB联合PDD治疗晚期非小细胞肺癌的疗效，作者自1995年2月～1997年6月，设计了两组方案。方法：治疗组NVB25mg／M，第1、15天静注，NVB12.5mg／M，第8天静注。对照组：NVB25mg／M第1、8天静注。两组方案均同时并用PDD4Omg第l～3天静滴。结果：治疗组12例，对照组30例。治疗组：治疗12例，PR5例，有效率41．7％。对照组治疗30例，PR14例，有效率46．7％。两组疗效经统计学处理差异无显著性。而治疗组毒副反应明显多于对照组，尤以Ⅲ度以上血液毒性最为显著。结论：对体质差，骨髓储备能力差的老年晚期肺癌病人，作者认为以NVB25mg/M连用两周联合治疗为宜。
Objective: To explore the efficacy of different doses of NVB combined with PDD in the treatment of advanced non-small cell lung cancer, the authors designed two groups of protocols from February 1995 to June 1997. Methods: In the treatment group, NVB was 25 mg/M, intravenously on the 1st and 15th days, NVB was 12.5 mg/M, and on the 8th day of intravenous injection. Control group: NVB 25mg/M intravenous injection on days 1 and 8. Both groups of protocols used PDD4Omg at the same time for the first to third days. Results: There were 12 patients in the treatment group and 30 in the control group. Treatment group: 12 cases were treated, 5 cases were PR, and the effective rate was 41.7%. In the control group, 30 cases were treated, and 14 cases were PR. The effective rate was 46.7%. There was no significant difference in the efficacy of the two groups after statistical analysis. The toxicity of the treatment group was significantly more than the control group, especially the blood toxicity above the third degree was the most significant. Conclusion: For elderly patients with advanced lung cancer with poor constitution and poor bone marrow storage ability, the authors believe that it is appropriate to use NVB 25 mg/M for two weeks combined therapy.